Entera Bio (ENTX) Operating Margin (2019 - 2025)

Entera Bio (ENTX) has reported Operating Margin for 6 consecutive years, with 6102.38% the latest figure, recorded in Q1 2025.

• Quarterly Operating Margin changed N/A year-over-year to 6102.38% in Q1 2025, while the trailing twelve-month figure through Dec 2025 was 27600.0% (down 2228508.0% YoY) and the FY2025 annual result came in at 27450.0%, down 2215442.0% from the prior year.
• Operating Margin slipped to 6102.38% in Q1 2025 per ENTX's latest filing, from 2850.0% in the prior quarter.
• Over the last five years, Operating Margin for ENTX reached as high as 1489.81% in Q1 2021 and fell as low as 35812.5% in Q3 2022.
• A 4-year average of 8281.72% and a median of 4749.68% in 2022 frame the typical range for Operating Margin.
• Annual changes were most pronounced in 2021 — Operating Margin soared 442489 bps — and 2022, when it slumped 3351250 bps.
• Year by year, Operating Margin stood at 2477.58% in 2021, then slumped by 785 bps to 21914.29% in 2022, then jumped by 87 bps to 2850.0% in 2024, then tumbled by 114 bps to 6102.38% in 2025.
• According to Business Quant data, Operating Margin over the past three periods registered 6102.38%, 2850.0%, and 7192.86% for Q1 2025, Q4 2024, and Q3 2024 respectively.